Author: Konjević Gordana Jović Viktor Jurišić Vladimir Radulović Siniša Jelić Svetislav Spužić Ivan
Publisher: Springer Publishing Company
ISSN: 0262-0898
Source: Clinical and Experimental Metastasis, Vol.20, Iss.7, 2003-11, pp. : 647-655
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Considering that well-defined and comprehensive immunological monitoring is the basis for the evaluation of the obtained immunmodulatory effects, we evaluated NK-cell activity, the number of CD3+CD4+, CD3+CD8+ T cells and CD16+CD56+ NK cells, as well as the expression of activation antigens, CD69, CD38 and HLA-DR on CD56+ NK cells, CD8+ and CD3+ T cells, simultaneously with IL-2 and TNF-α production, during chemoimmunotherapy with dacarbazine (DTIC) and interferon-α (IFN-α) in 39 patients with metastatic melanoma. In the first cycle of therapy, there was a significant rise in NK-cell activity, CD4+ T helper cell number, CD4/CD8 T-cell ratio, and the expression of activation antigens CD69 and CD38, on NK and T cells, respectively. However, in the following cycles there was a significant increase only in activation antigens without an increase in the percent or activity of NK cells. The early, but transient, immunopotentiation, present only in the first cycle of combined DTIC and IFN-α therapy, suggests that, in spite of increased IL-2 level, associated with augmented NK-cell activity, this therapy has a limited effect probably owing to the adverse effect of persistently high level of TNF-α in metastatic disease.
Related content
By Konjević Gordana Mirjačić Martinović Katarina Vuletić Ana Jović Viktor Jurisić Vladimir Babović Nada Spužić Ivan
Clinical and Experimental Metastasis, Vol. 24, Iss. 1, 2007-03 ,pp. :
By Gu Tao Kilinc Mehmet Egilmez Nejat
Cancer Immunology, Immunotherapy, Vol. 57, Iss. 7, 2008-07 ,pp. :
Cancer Chemotherapy and Pharmacology, Vol. 61, Iss. 6, 2008-05 ,pp. :